JPRN-jRCT2080224127已完成1 期
A Study to Evaluate CTX-712 in Advanced, Relapsed or Refractory Malignant Cancer Patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 79
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Subjects must have an advanced, relapsed or refractory cancer
- •- For a cohort of hematological cancers,subjects must have an MDS, CMML or AML (excluding APL) according to World Health Organization (WHO) criteria.
- •- As for MDS, subjects must be considered an intermediate, high, or very high risk according to the Revised International Prognostic Scoring System (IPSS-R)
- •2) Subjects must relapse or refractory to standard therapies, or not eligible for standard therapies.
- •3) Subjects must be an eastern cooperative oncology group (ECOG) performance status of 0 or 1
- •4) Subjects must have more than 90 days life expectancy
- •5) Subjects must have adequate major organ functions
排除标准
- •1) Patients with uncontrolled complications
- •2) Patients with active multiple primary cancers that require specific treatments
- •3) In a cohort of hematologic cancer patients, those who have received allogenic hematopoietic stem cell transplantation
- •4) Patients having a medical history of congenital retinal degenerative disease,optic nerve or retinal diseases
研究者
相似试验
进行中（未招募）
1 期
Effect of CT1812 Treatment on Aß Oligomer Displacement into CSFSponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2018-000163-89-SECognition Therapeutics, Inc.18
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-BETaiho Oncology, Inc.128
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-ESAstex Pharmaceuticals, Inc.168
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)ower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)MedDRA version: 20.0Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 27.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003281-40-DETaiho Oncology, Inc.168
进行中（未招募）
1 期
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)EUCTR2019-003281-40-ITASTEX PHARMACEUTICALS128